THE RISK OF MALARIAL INFECTIONS AND DISEASE IN PAPUA NEW GUINEAN CHILDREN

In a treatment re-infection study of 206 Papua New Guinean school children, we examined risk of reinfection and symptomatic malaria caused by different Plasmodium species. Although children acquired a similar number of polymerase chain reaction-detectable Plasmodium falciparum and P. vivax infection...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of tropical medicine and hygiene 2007-06, Vol.76 (6), p.997-1008
Hauptverfasser: MICHON, PASCAL, COLE-TOBIAN, JENNIFER L, DABOD, ELIJAH, SCHOEPFLIN, SONJA, IGU, JENNIFER, SUSAPU, MELINDA, TARONGKA, NANDAO, ZIMMERMAN, PETER A, REEDER, JOHN C, BEESON, JAMES G, SCHOFIELD, LOUIS, KING, CHRISTOPHER L, MUELLER, IVO
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1008
container_issue 6
container_start_page 997
container_title The American journal of tropical medicine and hygiene
container_volume 76
creator MICHON, PASCAL
COLE-TOBIAN, JENNIFER L
DABOD, ELIJAH
SCHOEPFLIN, SONJA
IGU, JENNIFER
SUSAPU, MELINDA
TARONGKA, NANDAO
ZIMMERMAN, PETER A
REEDER, JOHN C
BEESON, JAMES G
SCHOFIELD, LOUIS
KING, CHRISTOPHER L
MUELLER, IVO
description In a treatment re-infection study of 206 Papua New Guinean school children, we examined risk of reinfection and symptomatic malaria caused by different Plasmodium species. Although children acquired a similar number of polymerase chain reaction-detectable Plasmodium falciparum and P. vivax infections in six months of active follow-up (P. falciparum = 5.00, P. vivax = 5.28), they were 21 times more likely to develop symptomatic P. falciparum malaria (1.17/year) than P. vivax malaria (0.06/year). Children greater than nine years of age had a reduced risk of acquiring P. vivax infections of low-to-moderate (>150/microL) density (adjusted hazard rate [AHR] = 0.65 and 0.42), whereas similar reductions in risk with age of P. falciparum infection was only seen for parasitemias > 5,000/microL (AHR = 0.49) and symptomatic episodes (AHR = 0.51). Infection and symptomatic episodes with P. malariae and P. ovale were rare. By nine years of age, children have thus acquired almost complete clinical immunity to P. vivax characterized by a very tight control of parasite density, whereas the acquisition of immunity to symptomatic P. falciparum malaria remained incomplete. These observations suggest that different mechanisms of immunity may be important for protection from these malaria species.
doi_str_mv 10.4269/ajtmh.2007.76.997
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3740942</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70598609</sourcerecordid><originalsourceid>FETCH-LOGICAL-c554t-f48fca04e5ee98521bce41a37a775460560fe3aed499b18e7f5647f1d7d39a2c3</originalsourceid><addsrcrecordid>eNqFkU2P0zAQhi0EYsvCD-CCfIFbiu3YnviCZLXpNiKkq36Io-W6zjarpNmNWyr-_Wa3FYUTp5E8z7wz1oPQR0qGnEn11d7vm-2QEQJDkEOl4BUaUA4yopKL12hACGGRkjFcoXch3BNCE0bpW3RFQQgpCR2gbDlN8TxbfMezCf6hcz3PdI6zYpKOltmsWGBdjPE4W6R6kfbP-FbfrjQu0p_4ZpUVqS7waJrl43lavEdvSlsH_-Fcr9Fqki5H0yif3WQjnUdOCL6PSp6UzhLuhfcqEYyunefUxmABBJdESFL62PoNV2pNEw-lkBxKuoFNrCxz8TX6dsp9OKwbv3F-t-9sbR66qrHdb9Payvzb2VVbc9f-MjFwojjrA76cA7r28eDD3jRVcL6u7c63h2CACJVIov4LMgJMCIAepCfQdW0InS__XEOJeTZlXkyZZ1MGpOlN9TOf_v7GZeKspgc-nwEbnK3Lzu5cFS5cknAqmbpw2-pue6w6b0Jj67qPpeZ4PPbrTgufAM-Eo7g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20725577</pqid></control><display><type>article</type><title>THE RISK OF MALARIAL INFECTIONS AND DISEASE IN PAPUA NEW GUINEAN CHILDREN</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>MICHON, PASCAL ; COLE-TOBIAN, JENNIFER L ; DABOD, ELIJAH ; SCHOEPFLIN, SONJA ; IGU, JENNIFER ; SUSAPU, MELINDA ; TARONGKA, NANDAO ; ZIMMERMAN, PETER A ; REEDER, JOHN C ; BEESON, JAMES G ; SCHOFIELD, LOUIS ; KING, CHRISTOPHER L ; MUELLER, IVO</creator><creatorcontrib>MICHON, PASCAL ; COLE-TOBIAN, JENNIFER L ; DABOD, ELIJAH ; SCHOEPFLIN, SONJA ; IGU, JENNIFER ; SUSAPU, MELINDA ; TARONGKA, NANDAO ; ZIMMERMAN, PETER A ; REEDER, JOHN C ; BEESON, JAMES G ; SCHOFIELD, LOUIS ; KING, CHRISTOPHER L ; MUELLER, IVO</creatorcontrib><description>In a treatment re-infection study of 206 Papua New Guinean school children, we examined risk of reinfection and symptomatic malaria caused by different Plasmodium species. Although children acquired a similar number of polymerase chain reaction-detectable Plasmodium falciparum and P. vivax infections in six months of active follow-up (P. falciparum = 5.00, P. vivax = 5.28), they were 21 times more likely to develop symptomatic P. falciparum malaria (1.17/year) than P. vivax malaria (0.06/year). Children greater than nine years of age had a reduced risk of acquiring P. vivax infections of low-to-moderate (&gt;150/microL) density (adjusted hazard rate [AHR] = 0.65 and 0.42), whereas similar reductions in risk with age of P. falciparum infection was only seen for parasitemias &gt; 5,000/microL (AHR = 0.49) and symptomatic episodes (AHR = 0.51). Infection and symptomatic episodes with P. malariae and P. ovale were rare. By nine years of age, children have thus acquired almost complete clinical immunity to P. vivax characterized by a very tight control of parasite density, whereas the acquisition of immunity to symptomatic P. falciparum malaria remained incomplete. These observations suggest that different mechanisms of immunity may be important for protection from these malaria species.</description><identifier>ISSN: 0002-9637</identifier><identifier>EISSN: 1476-1645</identifier><identifier>DOI: 10.4269/ajtmh.2007.76.997</identifier><identifier>PMID: 17556601</identifier><identifier>CODEN: AJTHAB</identifier><language>eng</language><publisher>Lawrence, KS: ASTMH</publisher><subject>Adolescent ; Animals ; Antibodies, Protozoan - blood ; Antimalarials - therapeutic use ; Artemisinins - therapeutic use ; Biological and medical sciences ; Child ; Child, Preschool ; DNA, Protozoan - chemistry ; DNA, Protozoan - genetics ; Female ; Human protozoal diseases ; Humans ; Incidence ; Infectious diseases ; Longitudinal Studies ; Malaria ; Malaria, Falciparum - drug therapy ; Malaria, Falciparum - epidemiology ; Malaria, Falciparum - immunology ; Malaria, Vivax - drug therapy ; Malaria, Vivax - epidemiology ; Malaria, Vivax - immunology ; Male ; Medical sciences ; Papua New Guinea - epidemiology ; Parasitemia - drug therapy ; Parasitemia - epidemiology ; Parasitemia - immunology ; Parasitic diseases ; Plasmodium falciparum ; Plasmodium falciparum - genetics ; Plasmodium falciparum - immunology ; Plasmodium vivax - genetics ; Plasmodium vivax - immunology ; Polymerase Chain Reaction ; Protozoal diseases ; Risk Factors ; Rural Population ; Sesquiterpenes - therapeutic use</subject><ispartof>The American journal of tropical medicine and hygiene, 2007-06, Vol.76 (6), p.997-1008</ispartof><rights>2007 INIST-CNRS</rights><rights>Copyright © 2007 by The American Society of Tropical Medicine and Hygiene 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c554t-f48fca04e5ee98521bce41a37a775460560fe3aed499b18e7f5647f1d7d39a2c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18841629$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17556601$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MICHON, PASCAL</creatorcontrib><creatorcontrib>COLE-TOBIAN, JENNIFER L</creatorcontrib><creatorcontrib>DABOD, ELIJAH</creatorcontrib><creatorcontrib>SCHOEPFLIN, SONJA</creatorcontrib><creatorcontrib>IGU, JENNIFER</creatorcontrib><creatorcontrib>SUSAPU, MELINDA</creatorcontrib><creatorcontrib>TARONGKA, NANDAO</creatorcontrib><creatorcontrib>ZIMMERMAN, PETER A</creatorcontrib><creatorcontrib>REEDER, JOHN C</creatorcontrib><creatorcontrib>BEESON, JAMES G</creatorcontrib><creatorcontrib>SCHOFIELD, LOUIS</creatorcontrib><creatorcontrib>KING, CHRISTOPHER L</creatorcontrib><creatorcontrib>MUELLER, IVO</creatorcontrib><title>THE RISK OF MALARIAL INFECTIONS AND DISEASE IN PAPUA NEW GUINEAN CHILDREN</title><title>The American journal of tropical medicine and hygiene</title><addtitle>Am J Trop Med Hyg</addtitle><description>In a treatment re-infection study of 206 Papua New Guinean school children, we examined risk of reinfection and symptomatic malaria caused by different Plasmodium species. Although children acquired a similar number of polymerase chain reaction-detectable Plasmodium falciparum and P. vivax infections in six months of active follow-up (P. falciparum = 5.00, P. vivax = 5.28), they were 21 times more likely to develop symptomatic P. falciparum malaria (1.17/year) than P. vivax malaria (0.06/year). Children greater than nine years of age had a reduced risk of acquiring P. vivax infections of low-to-moderate (&gt;150/microL) density (adjusted hazard rate [AHR] = 0.65 and 0.42), whereas similar reductions in risk with age of P. falciparum infection was only seen for parasitemias &gt; 5,000/microL (AHR = 0.49) and symptomatic episodes (AHR = 0.51). Infection and symptomatic episodes with P. malariae and P. ovale were rare. By nine years of age, children have thus acquired almost complete clinical immunity to P. vivax characterized by a very tight control of parasite density, whereas the acquisition of immunity to symptomatic P. falciparum malaria remained incomplete. These observations suggest that different mechanisms of immunity may be important for protection from these malaria species.</description><subject>Adolescent</subject><subject>Animals</subject><subject>Antibodies, Protozoan - blood</subject><subject>Antimalarials - therapeutic use</subject><subject>Artemisinins - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>DNA, Protozoan - chemistry</subject><subject>DNA, Protozoan - genetics</subject><subject>Female</subject><subject>Human protozoal diseases</subject><subject>Humans</subject><subject>Incidence</subject><subject>Infectious diseases</subject><subject>Longitudinal Studies</subject><subject>Malaria</subject><subject>Malaria, Falciparum - drug therapy</subject><subject>Malaria, Falciparum - epidemiology</subject><subject>Malaria, Falciparum - immunology</subject><subject>Malaria, Vivax - drug therapy</subject><subject>Malaria, Vivax - epidemiology</subject><subject>Malaria, Vivax - immunology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Papua New Guinea - epidemiology</subject><subject>Parasitemia - drug therapy</subject><subject>Parasitemia - epidemiology</subject><subject>Parasitemia - immunology</subject><subject>Parasitic diseases</subject><subject>Plasmodium falciparum</subject><subject>Plasmodium falciparum - genetics</subject><subject>Plasmodium falciparum - immunology</subject><subject>Plasmodium vivax - genetics</subject><subject>Plasmodium vivax - immunology</subject><subject>Polymerase Chain Reaction</subject><subject>Protozoal diseases</subject><subject>Risk Factors</subject><subject>Rural Population</subject><subject>Sesquiterpenes - therapeutic use</subject><issn>0002-9637</issn><issn>1476-1645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2P0zAQhi0EYsvCD-CCfIFbiu3YnviCZLXpNiKkq36Io-W6zjarpNmNWyr-_Wa3FYUTp5E8z7wz1oPQR0qGnEn11d7vm-2QEQJDkEOl4BUaUA4yopKL12hACGGRkjFcoXch3BNCE0bpW3RFQQgpCR2gbDlN8TxbfMezCf6hcz3PdI6zYpKOltmsWGBdjPE4W6R6kfbP-FbfrjQu0p_4ZpUVqS7waJrl43lavEdvSlsH_-Fcr9Fqki5H0yif3WQjnUdOCL6PSp6UzhLuhfcqEYyunefUxmABBJdESFL62PoNV2pNEw-lkBxKuoFNrCxz8TX6dsp9OKwbv3F-t-9sbR66qrHdb9Payvzb2VVbc9f-MjFwojjrA76cA7r28eDD3jRVcL6u7c63h2CACJVIov4LMgJMCIAepCfQdW0InS__XEOJeTZlXkyZZ1MGpOlN9TOf_v7GZeKspgc-nwEbnK3Lzu5cFS5cknAqmbpw2-pue6w6b0Jj67qPpeZ4PPbrTgufAM-Eo7g</recordid><startdate>20070601</startdate><enddate>20070601</enddate><creator>MICHON, PASCAL</creator><creator>COLE-TOBIAN, JENNIFER L</creator><creator>DABOD, ELIJAH</creator><creator>SCHOEPFLIN, SONJA</creator><creator>IGU, JENNIFER</creator><creator>SUSAPU, MELINDA</creator><creator>TARONGKA, NANDAO</creator><creator>ZIMMERMAN, PETER A</creator><creator>REEDER, JOHN C</creator><creator>BEESON, JAMES G</creator><creator>SCHOFIELD, LOUIS</creator><creator>KING, CHRISTOPHER L</creator><creator>MUELLER, IVO</creator><general>ASTMH</general><general>Allen Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U1</scope><scope>7U2</scope><scope>C1K</scope><scope>M7N</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20070601</creationdate><title>THE RISK OF MALARIAL INFECTIONS AND DISEASE IN PAPUA NEW GUINEAN CHILDREN</title><author>MICHON, PASCAL ; COLE-TOBIAN, JENNIFER L ; DABOD, ELIJAH ; SCHOEPFLIN, SONJA ; IGU, JENNIFER ; SUSAPU, MELINDA ; TARONGKA, NANDAO ; ZIMMERMAN, PETER A ; REEDER, JOHN C ; BEESON, JAMES G ; SCHOFIELD, LOUIS ; KING, CHRISTOPHER L ; MUELLER, IVO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c554t-f48fca04e5ee98521bce41a37a775460560fe3aed499b18e7f5647f1d7d39a2c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adolescent</topic><topic>Animals</topic><topic>Antibodies, Protozoan - blood</topic><topic>Antimalarials - therapeutic use</topic><topic>Artemisinins - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>DNA, Protozoan - chemistry</topic><topic>DNA, Protozoan - genetics</topic><topic>Female</topic><topic>Human protozoal diseases</topic><topic>Humans</topic><topic>Incidence</topic><topic>Infectious diseases</topic><topic>Longitudinal Studies</topic><topic>Malaria</topic><topic>Malaria, Falciparum - drug therapy</topic><topic>Malaria, Falciparum - epidemiology</topic><topic>Malaria, Falciparum - immunology</topic><topic>Malaria, Vivax - drug therapy</topic><topic>Malaria, Vivax - epidemiology</topic><topic>Malaria, Vivax - immunology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Papua New Guinea - epidemiology</topic><topic>Parasitemia - drug therapy</topic><topic>Parasitemia - epidemiology</topic><topic>Parasitemia - immunology</topic><topic>Parasitic diseases</topic><topic>Plasmodium falciparum</topic><topic>Plasmodium falciparum - genetics</topic><topic>Plasmodium falciparum - immunology</topic><topic>Plasmodium vivax - genetics</topic><topic>Plasmodium vivax - immunology</topic><topic>Polymerase Chain Reaction</topic><topic>Protozoal diseases</topic><topic>Risk Factors</topic><topic>Rural Population</topic><topic>Sesquiterpenes - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MICHON, PASCAL</creatorcontrib><creatorcontrib>COLE-TOBIAN, JENNIFER L</creatorcontrib><creatorcontrib>DABOD, ELIJAH</creatorcontrib><creatorcontrib>SCHOEPFLIN, SONJA</creatorcontrib><creatorcontrib>IGU, JENNIFER</creatorcontrib><creatorcontrib>SUSAPU, MELINDA</creatorcontrib><creatorcontrib>TARONGKA, NANDAO</creatorcontrib><creatorcontrib>ZIMMERMAN, PETER A</creatorcontrib><creatorcontrib>REEDER, JOHN C</creatorcontrib><creatorcontrib>BEESON, JAMES G</creatorcontrib><creatorcontrib>SCHOFIELD, LOUIS</creatorcontrib><creatorcontrib>KING, CHRISTOPHER L</creatorcontrib><creatorcontrib>MUELLER, IVO</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The American journal of tropical medicine and hygiene</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MICHON, PASCAL</au><au>COLE-TOBIAN, JENNIFER L</au><au>DABOD, ELIJAH</au><au>SCHOEPFLIN, SONJA</au><au>IGU, JENNIFER</au><au>SUSAPU, MELINDA</au><au>TARONGKA, NANDAO</au><au>ZIMMERMAN, PETER A</au><au>REEDER, JOHN C</au><au>BEESON, JAMES G</au><au>SCHOFIELD, LOUIS</au><au>KING, CHRISTOPHER L</au><au>MUELLER, IVO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>THE RISK OF MALARIAL INFECTIONS AND DISEASE IN PAPUA NEW GUINEAN CHILDREN</atitle><jtitle>The American journal of tropical medicine and hygiene</jtitle><addtitle>Am J Trop Med Hyg</addtitle><date>2007-06-01</date><risdate>2007</risdate><volume>76</volume><issue>6</issue><spage>997</spage><epage>1008</epage><pages>997-1008</pages><issn>0002-9637</issn><eissn>1476-1645</eissn><coden>AJTHAB</coden><abstract>In a treatment re-infection study of 206 Papua New Guinean school children, we examined risk of reinfection and symptomatic malaria caused by different Plasmodium species. Although children acquired a similar number of polymerase chain reaction-detectable Plasmodium falciparum and P. vivax infections in six months of active follow-up (P. falciparum = 5.00, P. vivax = 5.28), they were 21 times more likely to develop symptomatic P. falciparum malaria (1.17/year) than P. vivax malaria (0.06/year). Children greater than nine years of age had a reduced risk of acquiring P. vivax infections of low-to-moderate (&gt;150/microL) density (adjusted hazard rate [AHR] = 0.65 and 0.42), whereas similar reductions in risk with age of P. falciparum infection was only seen for parasitemias &gt; 5,000/microL (AHR = 0.49) and symptomatic episodes (AHR = 0.51). Infection and symptomatic episodes with P. malariae and P. ovale were rare. By nine years of age, children have thus acquired almost complete clinical immunity to P. vivax characterized by a very tight control of parasite density, whereas the acquisition of immunity to symptomatic P. falciparum malaria remained incomplete. These observations suggest that different mechanisms of immunity may be important for protection from these malaria species.</abstract><cop>Lawrence, KS</cop><pub>ASTMH</pub><pmid>17556601</pmid><doi>10.4269/ajtmh.2007.76.997</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0002-9637
ispartof The American journal of tropical medicine and hygiene, 2007-06, Vol.76 (6), p.997-1008
issn 0002-9637
1476-1645
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3740942
source MEDLINE; Alma/SFX Local Collection
subjects Adolescent
Animals
Antibodies, Protozoan - blood
Antimalarials - therapeutic use
Artemisinins - therapeutic use
Biological and medical sciences
Child
Child, Preschool
DNA, Protozoan - chemistry
DNA, Protozoan - genetics
Female
Human protozoal diseases
Humans
Incidence
Infectious diseases
Longitudinal Studies
Malaria
Malaria, Falciparum - drug therapy
Malaria, Falciparum - epidemiology
Malaria, Falciparum - immunology
Malaria, Vivax - drug therapy
Malaria, Vivax - epidemiology
Malaria, Vivax - immunology
Male
Medical sciences
Papua New Guinea - epidemiology
Parasitemia - drug therapy
Parasitemia - epidemiology
Parasitemia - immunology
Parasitic diseases
Plasmodium falciparum
Plasmodium falciparum - genetics
Plasmodium falciparum - immunology
Plasmodium vivax - genetics
Plasmodium vivax - immunology
Polymerase Chain Reaction
Protozoal diseases
Risk Factors
Rural Population
Sesquiterpenes - therapeutic use
title THE RISK OF MALARIAL INFECTIONS AND DISEASE IN PAPUA NEW GUINEAN CHILDREN
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T05%3A55%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=THE%20RISK%20OF%20MALARIAL%20INFECTIONS%20AND%20DISEASE%20IN%20PAPUA%20NEW%20GUINEAN%20CHILDREN&rft.jtitle=The%20American%20journal%20of%20tropical%20medicine%20and%20hygiene&rft.au=MICHON,%20PASCAL&rft.date=2007-06-01&rft.volume=76&rft.issue=6&rft.spage=997&rft.epage=1008&rft.pages=997-1008&rft.issn=0002-9637&rft.eissn=1476-1645&rft.coden=AJTHAB&rft_id=info:doi/10.4269/ajtmh.2007.76.997&rft_dat=%3Cproquest_pubme%3E70598609%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20725577&rft_id=info:pmid/17556601&rfr_iscdi=true